Citation Impact
Citing Papers
MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity
2009
Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy
2012
Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease
2020
Graft microvascular disease in solid organ transplantation
2014 StandoutNobel
Activity-independent targeting of mTOR to lysosomes in primary osteoclasts
2017
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Role of anti-vimentin antibodies in allograft rejection
2013
Gastric cancer
2016 Standout
Intracellular Delivery System for Antibody–Peptide Drug Conjugates
2015 StandoutNobel
β-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation
2009 StandoutNobel
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
2010
Living Radical Polymerization by the RAFT Process – A Third Update
2012 Standout
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8+ effector T cell responses
2016
Fracture healing: mechanisms and interventions
2014 Standout
Targeting hypoxia in cancer therapy
2011 Standout
Rheumatoid arthritis
2018 Standout
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
Chronic inflammation in the etiology of disease across the life span
2019 Standout
A Chemical Glycoproteomics Platform Reveals O-GlcNAcylation of Mitochondrial Voltage-Dependent Anion Channel 2
2013 StandoutNobel
Melanoma: New Insights and New Therapies
2012
PLGA-based nanoparticles: An overview of biomedical applications
2012 Standout
18F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer
2013
mTOR signaling and drug development in cancer
2010
Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery
2007
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
HCVpro: Hepatitis C virus protein interaction database
2011
Hepatocellular carcinoma
2021 Standout
Application of RNA interference in treating human diseases
2010
Survival and apoptosis: a dysregulated balance in liver cancer
2007
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines
2015 StandoutNobel
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
EGFR tyrosine kinase inhibition induces autophagy in cancer cells
2012
Recent advances in the development of Mcl-1 inhibitors for cancer therapy
2019
WNT signaling in bone homeostasis and disease: from human mutations to treatments
2013 Standout
Hepatocyte IKKβ/NF-κB Inhibits Tumor Promotion and Progression by Preventing Oxidative Stress-Driven STAT3 Activation
2010
MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway
2013
Targeting apoptosis in cancer therapy
2020 Standout
Aging, Obesity, and Inflammatory Age-Related Diseases
2017
Osteoporosis, bone mineral density and CKD–MBD: treatment considerations
2017
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis
2013 StandoutNobel
Targeting the hypoxia-inducible factor (HIF) pathway in cancer
2009
Oxidative Stress in Cancer
2020 Standout
STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo
2011
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Upregulation of Mcl-1 inhibits JQ1-triggered anticancer activity in hepatocellular carcinoma cells
2017
Recent agents targeting HIF‐1α for cancer therapy
2012
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2013 Standout
Effects of Microrna-29 on Apoptosis, Tumorigenicity, and Prognosis of Hepatocellular Carcinoma
2009
Overexpression of Mcl-1L Splice Variant Is Associated with Poor Prognosis and Chemoresistance in Oral Cancers
2014
BCL-2 family isoforms in apoptosis and cancer
2019 Standout
Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries
2014
Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration
2012
Unmet needs and challenges in gastric cancer: The way forward
2014
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
2014 Standout
The PI3K Pathway in Human Disease
2017 Standout
Targeting the Bcl-2 family for cancer therapy
2012
Cationic Nanohydrogel Particles as Potential siRNA Carriers for Cellular Delivery
2012
Defining trained immunity and its role in health and disease
2020 Standout
VDAC, a multi-functional mitochondrial protein regulating cell life and death
2010
Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway
2018
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
2018 Standout
Regulatory networks defining EMT during cancer initiation and progression
2013 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Early chronic kidney disease–mineral bone disorder stimulates vascular calcification
2013
Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison
2017
Natural polyphenols: An overview
2016 Standout
Hepatocellular Carcinoma
2019 Standout
Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover
2011
Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death
2015
Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration
2021 Standout
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
2012
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer
2008
Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer
2016 StandoutNobel
Hepatitis C Virus and Cellular Stress Response: Implications to Molecular Pathogenesis of Liver Diseases
2012
The effect of particle design on cellular internalization pathways
2008 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Therapeutic targeting of trained immunity
2019
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
2013
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
2014 Standout
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
2014
Flavonoids in Cancer and Apoptosis
2018 Standout
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Mechanisms of Renal Fibrosis
2017 Standout
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
2020 Standout
UV Radiation and the Skin
2013 Standout
A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation
2008
Robust Distal Tip Cell Pathfinding in the Face of Temperature Stress Is Ensured by Two Conserved microRNAS inCaenorhabditis elegans
2015 StandoutNobel
Calcium phosphates in biomedical applications: materials for the future?
2015 Standout
Works of Daniel Cejka being referenced
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
2009
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
2010
Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells
2006
Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo
2010
Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis
2010
mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo
2010
Sclerostin and Dickkopf-1 in Renal Osteodystrophy
2010
Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy
2005
Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo
2008
Vertical Inhibition of the mTORC1/mTORC2/PI3K Pathway Shows Synergistic Effects against Melanoma In Vitro and In Vivo
2010
Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients
2011
Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH<sub>1–34</sub>): A Pilot Study
2010
Renal Elimination of Sclerostin Increases With Declining Kidney Function
2013
Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation
2007
mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
2009
Short interfering RNA (siRNA): tool or therapeutic?
2005
Identification of Non-HLA Antigens Targeted by Alloreactive Antibodies in Patients Undergoing Chronic Hemodialysis
2010